DCB-developed cancer drug is cleared for phase I trials in Taiwan
TAIPEI, Taiwan – Taiwan's government-funded Development Center for Biotechnology (DCB) said this week that its mTOR inhibitor cancer drug candidate, DCBCI0901, developed in-house and licensed out in 2011 to an alliance of four local pharmaceutical companies, received approval from the FDA and the TFDA to begin phase I trials.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter